CINECA IRIS Institutional Research Information System

NOVELLI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.514
EU - Europa 9.471
AS - Asia 6.402
AF - Africa 218
SA - Sud America 116
OC - Oceania 111
Continente sconosciuto - Info sul continente non disponibili 29
Totale 29.861
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.335
CN - Cina 3.848
IT - Italia 2.173
SE - Svezia 1.280
DE - Germania 962
IE - Irlanda 876
DK - Danimarca 727
FR - Francia 655
SG - Singapore 651
UA - Ucraina 645
FI - Finlandia 484
KR - Corea 425
AT - Austria 408
TW - Taiwan 369
GB - Regno Unito 358
PL - Polonia 307
JP - Giappone 224
VN - Vietnam 196
HK - Hong Kong 183
SN - Senegal 162
IN - India 146
CA - Canada 140
AU - Australia 100
NL - Olanda 96
BE - Belgio 95
TR - Turchia 89
ES - Italia 88
BR - Brasile 81
ID - Indonesia 81
RU - Federazione Russa 66
CH - Svizzera 47
GR - Grecia 46
IR - Iran 45
MX - Messico 35
IL - Israele 33
EU - Europa 26
RO - Romania 25
NO - Norvegia 20
HU - Ungheria 19
TH - Thailandia 17
UZ - Uzbekistan 17
PT - Portogallo 16
CZ - Repubblica Ceca 15
BY - Bielorussia 12
PK - Pakistan 12
MY - Malesia 11
NZ - Nuova Zelanda 11
EE - Estonia 9
IQ - Iraq 9
LU - Lussemburgo 9
MA - Marocco 9
MO - Macao, regione amministrativa speciale della Cina 9
MU - Mauritius 9
PE - Perù 9
EG - Egitto 8
NG - Nigeria 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
AR - Argentina 7
SA - Arabia Saudita 7
ZA - Sudafrica 7
BG - Bulgaria 5
LB - Libano 5
PH - Filippine 5
CL - Cile 4
CO - Colombia 4
HR - Croazia 4
MD - Moldavia 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
SK - Slovacchia (Repubblica Slovacca) 3
UG - Uganda 3
A1 - Anonimo 2
BN - Brunei Darussalam 2
CY - Cipro 2
DZ - Algeria 2
EC - Ecuador 2
ET - Etiopia 2
KE - Kenya 2
OM - Oman 2
PR - Porto Rico 2
RS - Serbia 2
SI - Slovenia 2
TN - Tunisia 2
VE - Venezuela 2
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
BT - Bhutan 1
BZ - Belize 1
CI - Costa d'Avorio 1
CU - Cuba 1
GH - Ghana 1
IM - Isola di Man 1
JO - Giordania 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
Totale 29.858
Salva come PNG Salva come JPEG
Città #
Chandler 1.974
Beijing 1.324
Ann Arbor 1.207
Dublin 873
Houston 736
Fairfield 641
Ashburn 604
Wilmington 526
Dearborn 452
Singapore 432
Torino 431
Jacksonville 422
Vienna 403
Nyköping 384
Guangzhou 379
Villeurbanne 351
Woodbridge 351
Princeton 291
Medford 284
Shanghai 273
Warsaw 273
Taipei 264
Fremont 246
Seattle 246
Cambridge 244
Redwood City 241
Pisa 193
Turin 188
Milan 183
Los Angeles 152
Dong Ket 133
Nanjing 125
Boardman 112
Rome 111
Boston 108
Hangzhou 97
Wuhan 86
Chengdu 81
Tokyo 79
Washington 79
Jakarta 77
Shenyang 67
San Diego 66
Brussels 65
New York 63
Munich 55
Verona 54
Norwalk 49
Santa Clara 47
Zhengzhou 45
Toronto 43
San Mateo 42
Kunming 41
Hong Kong 40
Jinan 38
Chongqing 37
Falls Church 37
Hefei 37
Xian 37
Helsinki 35
Changsha 34
Mountain View 34
Paris 34
Düsseldorf 33
Seoul 32
Phoenix 30
Tianjin 29
Changchun 27
Heidelberg 27
London 26
Hebei 24
Fortaleza 23
Frankfurt am Main 22
Melbourne 22
Nanchang 21
San Jose 21
Amsterdam 19
Ottawa 19
Pittsburgh 19
Shenzhen 19
Chicago 18
Harbin 18
Villadose 18
Fuzhou 17
Lanzhou 17
Menlo Park 17
Upper Marlboro 17
Central 16
Istanbul 16
Lachine 16
Polska 16
Rochester 16
Wayne 16
Detroit 15
Naples 15
Nürnberg 15
Philadelphia 15
Silver Spring 15
Wuxi 15
Barcelona 14
Totale 17.391
Salva come PNG Salva come JPEG
Nome #
Alpha-Enolase (ENO1), a potential target in novel immunotherapies 1.599
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer 1.540
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth 587
Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. 438
Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer. 427
Circulating Autoantibodies to Phosphorylated α-Enolase are a Hallmark of Pancreatic Cancer. 422
A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies 412
Molecular and genetic bases of pancreatic cancer 393
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 382
Regulation of Langerhans cell functions in a hypoxic environment 327
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers 320
Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mDCs: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. 299
The advanced glycation end-product Nϵ-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention 291
Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. 285
Dealing with indetermination in biochemical networks 274
Overcoming the Lack of Kinetic Information in Biochemical Reactions Networks 274
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis 270
Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2a receptor stimulation 255
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 244
CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells 239
Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients 227
Chemotherapy effects on immune-complexes in pancreatic ductal adenocarcinoma patients serum 222
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest 221
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients 221
Pancreatic cancer vaccine: a unique potential therapy 217
FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis 209
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells 207
Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma 204
Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response 202
α-enolase: a promising therapeutic and diagnostic tumor target 200
Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. 199
Proteomic data analysis of pancreatic cancer patient sera revealed how chemotherapy shapes the immunogenicity of developing tumors 197
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 196
STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? 195
Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression 195
Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype 187
Oxidative stress-mediated antimalarial activity of plakortin, a natural endoperoxide from the tropical sponge Plakortis simplex 186
Computational modeling of pancreatic cancer cells metabolism 186
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 185
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. 181
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 180
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. 179
Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways 174
An integrative transcriptomic analysis of glycolytic genes reveals distinct metabolic subtypes in pancreatic cancer 172
Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners 170
Inspecting energy releasing pathways by a combination of genomics data and mechanistic approach 170
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 168
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer 155
An integrated proteomic and physiological approach to understand the adhesion mechanism of the probiotic Lactobacillus reuteri Lb2 BM DSM 16143 151
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 147
Three are better than one: plasminogen receptors as cancer theranostic targets. 147
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 146
Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma 144
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 144
In pancreatic cancer chemotherapy increases anti-tumor responses to tumor associated antigens and potentiates DNA vaccination 143
Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma 141
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen 139
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 139
BLOCKADE OF SURFACE ALPHA-ENOLASE (ENO1) AS A NOVEL IMMUNOTHERAPEUTIC APPROACH IN PANCREATIC CANCER 134
Antibody and T cell response profiling of pancreatic cancer patients before and after chemotherapy reveals increased recognition of antigens suitable for immunotherapy 134
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 133
Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. 133
Antibody and T cell response profiling in pancreatic cancer patients before and after chemotherapy identify tumor associated antigens suitable for immunotherapy 129
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. 126
Generazione della diversità anticorpale 124
STAT1 and STAT3 in tumorigenesis: A matter of balance 124
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 122
Endogenous glutamine decrease is associated with pancreatic cancer progression 117
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 116
Neutralization of IL-10 And TGF beta 1 rescues T cells from tolerogenic mechanisms induced by HER2 vaccine in cancer patients 112
Computational modeling of the immune response in multiple sclerosis using epimod framework 112
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 110
Autoantibody signature in human ductal pancreatic adenocarcinoma 109
A Mouse To Human Autoantibody Signature in Pancreatic Ductal Adenocarcinoma 108
Next generation of cancer immunotherapy calls for combination 108
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 106
DNA vaccines coding for chimeric human/rat HER2 as innovative immunotherapeutic tools for the treatment of HER2+ cancer patients 105
DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer. 104
Adriamycin-induced proteinuria in nude mice: an immune-system-mediated toxic effect. 102
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 102
High Mobility Group Box 1 (hmgb1) Expands CD4+CD25+Foxp3+ T Cells and Increases the Expression of CD39 101
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 100
Human dendritic cells differentiated in hypoxia down modulate antigen uptake and change their chemokine expression profile 99
Identification of tumor associated antigens in pancreatic cancer by serological proteome analysis 99
A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. 98
Alpha-enolase elicits specific adenocarcinoma pancreatic-T cell responses in healthy donors and tumor patients 98
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 98
Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. 97
Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 cells affects cell cycle progression. 96
AN ISOLATED MONOPHOSPHORYLATED PEPTIDE DERIVED FROM HUMAN ALPHA-ENOLASE USEFUL FOR DIAGNOSIS AND TREATMENT OF PANCREATIC ADENOCARCINOMA, ANTIBODIES DIRECTED AGAINST THE SAID MONOPHOSPHORYLATED PEPTIDE, AND USES THEREOF 96
The dark side of immunotherapy: pancreatic cancer 95
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT 94
A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. 93
THE BLOCKADE OF PLASMINOGEN-ALPHA-ENOLASE INTERACTION INHIBITS THE INVASION OF PANCREATIC CANCER CELLS. 93
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 93
The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer 91
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 90
Proteomics-based evidence for a pro-oncogenic role of ESRP1 in human colorectal cancer cells 90
Dendritic cells transfected with ErbB-2 rat/human hybrid plasmid elicit an effective T cells response in ErbB-2+ cancer patients 89
Abstract 4984: Chemotherapy induces a coordinate autoantibody and T-cell response against tumor-associated antigens in pancreatic cancer patients 89
Totale 20.593
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.608
article - articoli 0
book - libri 0
conference - conferenze 23.476
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.325 0 0 0 565 375 829 531 333 523 450 398 321
2020/20214.099 412 267 331 274 433 354 306 236 440 316 296 434
2021/20223.845 160 167 172 389 222 223 273 247 137 359 778 718
2022/20235.322 503 470 114 643 473 1.250 337 390 592 137 239 174
2023/20243.145 314 380 199 130 254 353 115 155 29 149 476 591
2024/20251.835 367 537 574 357 0 0 0 0 0 0 0 0
Totale 30.871